Modelling approaches for angiogenesis

European Journal of Cancer

Volumn 40, Issue 6, 2004, Pages 881-889

  Taraboletti, G ^a   Giavazzi, R ^a  

^a MARIO NEGRI INST PHARMACOL RES   (Italy)

Author keywords

Angiogenesis; Angiogenesis inhibitors; Endothelial cells; Imaging; Preclinical assays; Tumour vasculature; Vascular targeting agents

Indexed keywords

ANGIOGENESIS INHIBITOR; MATRIGEL; VASCULAR TARGETING AGENT;

ANALYTIC METHOD; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; CANCER RESEARCH; CELL ACTIVITY; CELL ASSAY; CELL CULTURE; CELL INVASION; CELL ISOLATION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CHORIOALLANTOIS; CULTURE TECHNIQUE; DEGRADATION; DRUG ACTIVITY; DRUG DETERMINATION; DRUG RESEARCH; DRUG SCREENING; ENDOTHELIUM CELL; EX VIVO STUDY; EXPERIMENTAL MODEL; EXPERIMENTATION; EXTRACELLULAR MATRIX; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MICROSCOPY; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; PROTEOMICS; REVIEW; TUMOR MODEL; VASCULAR RING; VASCULARIZATION; ZEBRA FISH;

EID: 1942486863     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2004.01.002     Document Type: Article

References (53)

1. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature. 407:2000;249-257.
2. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1:1995;27-31.
3. Giavazzi R., Taraboletti G. Preclinical development of metalloproteasis inhibitors in cancer therapy. Crit. Rev. Oncol. Hematol. 37:2001;53-60.
4. Giavazzi R., Nicoletti M.I. Small molecules in anti-angiogenic therapy. Curr. Opin. Investig. Drugs. 3:2002;482-491.
5. Kerbel R., Folkman J. Clinical translation of angiogenesis inhibitors. Nat. Rev. Cancer. 2:2002;727-739.
6. Taraboletti G., Margosio B. Antiangiogenic and antivascular therapy for cancer. Current Opin. Pharmacol. 1:2001;378-384.
7. Chaplin D.J., Dougherty G.J. Tumour vasculature as a target for cancer therapy. Br. J. Cancer. 80(Suppl. 1):1999;57-64.
8. Vailhe B., Vittet D., Feige J.J. In vitro models of vasculogenesis and angiogenesis. Lab. Invest. 81:2001;439-452.
9. Auerbach R., Lewis R., Shinners B., Kubai L., Akhtar N. Angiogenesis assays. a critical overview Clin. Chem. 49:2003;32-40.
10. Jain R.K., Schlenger K., Hockel M., Yuan F. Quantitative angiogenesis assays. progress and problems Nat. Med. 3:1997;1203-1208.
11. Jain R.K., Munn L.L., Fukumura D. Dissecting tumour pathophysiology using intravital microscopy. Nat. Rev. Cancer. 2:2002;266-276.
12. Stacker S.A., Achen M.G., Jussila L., Baldwin M.E., Alitalo K. Lymphangiogenesis and cancer metastasis. Nat. Rev. Cancer. 2:2002;573-583.
13. Rafii S., Lyden D., Benezra R., Hattori K., Heissig B. Vascular and haematopoietic stem cells. novel targets for anti-angiogenesis therapy? Nat. Rev. Cancer. 2:2002;826-835.
14. St Croix B., Rago C., Velculescu V.et al. Genes expressed in human tumor endothelium. Science. 289:2000;1197-1202.
15. Alessandri G., Chirivi R.G., Fiorentini S.et al. Phenotypic and functional characteristics of tumour-derived microvascular endothelial cells. Clin. Exp. Metastasis. 17:1999;655-662.
16. Belotti D., Vergani V., Drudis T.et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin. Cancer Res. 2:1996;1843-1849.
17. Hanahan D., Bergers G., Bergsland E. Less is more, regularly. metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice J. Clin. Invest. 105:2000;1045-1047.
18. Klement G., Baruchel S., Rak J.et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. 105:2000;R15-R24.
19. Miller K.D., Sweeney C.J., Sledge G.W. Jr. Redefining the target. chemotherapeutics as antiangiogenics J. Clin. Oncol. 19:2001;1195-1206.
20. Taraboletti G., Roberts D., Liotta L.A., Giavazzi R. Platelet thrombospondin modulates endothelial cell adhesion, motility, and growth. a potential angiogenesis regulatory factor J. Cell Biol. 111:1990;765-772.
21. Taraboletti G., Belotti D., Dejana E., Mantovani A., Giavazzi R. Endothelial cell migration and invasiveness are induced by a soluble factor produced by murine endothelioma cells transformed by polyoma virus middle T oncogene. Cancer Res. 53:1993;3812-3816.
22. Taraboletti G., Garofalo A., Belotti D.et al. Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases. J. Natl. Cancer Inst. 87:1995;293-298.
23. Montesano R., Pepper M.S. Three-dimensional in vitro assay of endothelial cell invasion and capillary tube morphogenesis. Mironov C.D.L.D., Sage E.H. Vascular morphogenesis: in vivo, in vitro, in mente. 1998;79-110 Birkhäuser, Boston.
24. Micheletti G., Poli M., Borsotti P.et al. Vascular-targeting activity of ZD6126, a novel tubulin-binding agent. Cancer Res. 63:2003;1534-1537.
25. Feraud O., Vittet D. Murine embryonic stem cell in vitro differentiation. applications to the study of vascular development Histol. Histopathol. 18:2003;191-199.
26. Wartenberg M., Gunther J., Hescheler J., Sauer H. The embryoid body as a novel in vitro assay system for antiangiogenic agents. Lab. Invest. 78:1998;1301-1314.
27. Wartenberg M., Donmez F., Ling F.C., Acker H., Hescheler J., Sauer H. Tumor-induced angiogenesis studied in confrontation cultures of multicellular tumor spheroids and embryoid bodies grown from pluripotent embryonic stem cells. Faseb. J. 15:2001;995-1005.
28. Sauer H., Gunther J., Hescheler J., Wartenberg M. Thalidomide inhibits angiogenesis in embryoid bodies by the generation of hydroxyl radicals. Am. J. Pathol. 156:2000;151-158.
29. Nicosia R.F. The rat aorta model of angiogenesis and its applications. Mironov C.D.L.D., Sage E.H. Vascular morphogenesis: in vivo, in vitro, in mente. 1998;111-139 Birkhäuser, Boston.
30. Nicosia R.F., Ottinetti A. Growth of microvessels in serum-free matrix culture of rat aorta. A quantitative assay of angiogenesis in vitro. Lab. Invest. 63:1990;115-122.
31. Plunkett M.L., Hailey J.A. An in vivo quantitative angiogenesis model using tumor cells entrapped in alginate. Lab. Invest. 62:1990;510-517.
32. Passaniti A., Taylor R.M., Pili R.et al. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab. Invest. 67:1992;519-528.
33. Taraboletti G., Micheletti G., Giavazzi R., Riva A. IDN 5390. a new concept in taxane development Anticancer Drugs. 14:2003;255-258.
34. Gimbrone M.A. Jr., Cotran R.S., Leapman S.B., Folkman J. Tumor growth and neovascularization. an experimental model using the rabbit cornea J. Natl. Cancer Inst. 52:1974;413-427.
35. Chang L., Kaipainen A., Folkman J. Lymphangiogenesis new mechanisms. Ann. N. Y. Acad. Sci. 979:2002;111-119.
36. Ribatti D., Vacca A. Models for studying angiogenesis in vivo. Int. J. Biol. Markers. 14:1999;207-213.
37. Ribatti D., Nico B., Vacca A., Roncali L., Burri P.H., Djonov V. Chorioallantoic membrane capillary bed. a useful target for studying angiogenesis and anti-angiogenesis in vivo Anat. Rec. 264:2001;317-324.
38. Nguyen M., Shing Y., Folkman J. Quantitation of angiogenesis and antiangiogenesis in the chick embryo chorioallantoic membrane. Microvasc. Res. 47:1994;31-40.
39. Seandel M., Noack-Kunnmann K., Zhu D., Aimes R.T., Quigley J.P. Growth factor-induced angiogenesis in vivo requires specific cleavage of fibrillar type I collagen. Blood. 97:2001;2323-2332.
40. Jain R.K. Angiogenesis and lymphangiogenesis in tumors. insights from intravital microscopy Cold Spring Harb. Symp. Quant. Biol. 67:2002;239-248.
41. Chan J., Bayliss P.E., Wood J.M., Roberts T.M. Dissection of angiogenic signaling in zebrafish using a chemical genetic approach. Cancer Cell. 1:2002;257-267.
42. Cross L.M., Cook M.A., Lin S., Chen J.N., Rubinstein A.L. Rapid analysis of angiogenesis drugs in a live fluorescent zebrafish assay. Arterioscler. Thromb. Vasc. Biol. 23:2003;911-912.
43. O'Reilly M.S., Holmgren L., Shing Y.et al. Angiostatin. a circulating endothelial cell inhibitor that suppresses angiogenesis and tumor growth Cold Spring Harb. Symp. Quant. Biol. 59:1994;471-482.
44. Giavazzi R., Giuliani R., Coltrini D.et al. Modulation of tumor angiogenesis by conditional expression of fibroblast growth factor-2 affects early but not established tumors. Cancer Res. 61:2001;309-317.
45. Bergers G., Song S., Meyer-Morse N., Bergsland E., Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest. 111:2003;1287-1295.
46. Hlatky L., Hahnfeldt P., Folkman J. Clinical application of antiangiogenic therapy. microvessel density, what it does and doesn't tell us J. Natl. Cancer Inst. 94:2002;883-893.
47. McDonald D.M., Choyke P.L. Imaging of angiogenesis. from microscope to clinic Nat. Med. 9:2003;713-725.
48. Rudin M., Weissleder R. Molecular imaging in drug discovery and development. Nat. Rev. Drug Discov. 2:2003;123-131.
49. Neeman M., Dafni H. Structural, functional, and molecular MR imaging of the microvasculature Preclinical MRI experience in imaging angiogenesis. Annu. Rev. Biomed. Eng. 5:2003;29-56.
50. Arap W., Pasqualini R., Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science. 279:1998;377-380.
51. Joyce J.A., Laakkonen P., Bernasconi M., Bergers G., Ruoslahti E., Hanahan D. Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis. Cancer Cell. 4:2003;393-403.
52. Hoffman J.A., Giraudo E., Singh M.et al. Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma. Cancer Cell. 4:2003;383-391.
53. Michener C.M., Ardekani A.M., Petricoin 3rd E.F., Liotta L.A., Kohn E.C. Genomics and proteomics. application of novel technology to early detection and prevention of cancer Cancer Detect. Prev. 26:2002;249-255.